Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NEO Rad (LOW): Neoadjuvant Ipilimumab, Nivolumab, and SBRT in Resectable NSCLC
NCT04933903Phase 2Recruiting
- Sponsor
- Brown University
- Start
- Oct 2021
- Primary completion
- Oct 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of ipilimumab, nivolumab in non-small cell lung cancer (NSCLC), sponsored by Brown University. Started Oct 2021; status: recruiting.
02
Drugs
ipilimumabnivolumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04933903.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04933903.